Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anavex Life Sciences Corp.

http://www.anavex.com

Latest From Anavex Life Sciences Corp.

Acadia’s Daybue Gets First Approval In Rett Syndrome

Daybue is the first drug approved to treat the rare neurodevelopmental disorder Rett syndrome, despite high clinical trial incidence of diarrhea. Product labeling includes clinician guidance for the side effect.

Approvals Rare Diseases

New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data

The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.

Clinical Trials Companies

Anavex Reveals Positive Phase III Data In Rett Syndrome But A Surprise Endpoint

The endpoint used in the AVATAR trial was different than the one investors had expected; management said the change was made to satisfy the US FDA.

Neurology Clinical Trials

Acadia’s Trofinetide Shows Efficacy In Rett Syndrome, But Safety Looks Shaky

Trofinetide could be the first approved drug for Rett patients after hitting both co-primary endpoints in a Phase III trial, but high rates of diarrhea and vomiting raise questions.

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Anavex Australia Pty Ltd.
UsernamePublicRestriction

Register